VANCOUVER, Washington, Oct. 11, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and CEO, will present a corporate update at The MicroCap Rodeo Conference at 3:50 pm CT on Tuesday, October 15, 2019, in Austin and meet with interested conference attendees throughout the event. Dr. Pourhassan will present on, among other things, the status of the Company’s BLA filing for HIV, pre-clinical study results pertaining to certain cancer indications and the potential for leronlimab to reduce liver fibrosis, which is one of the clinical manifestations of non-alcoholic steatohepatitis (NASH). The conference will be held at 500 E. 4th Street, Austin, Texas. A live webcast of the presentation will be available at CytoDyn Presentation at MicroCap Rodeo or https://www.cytodyn.com see Latest Events. A replay of the presentation will be available for 90 days following the event. Web participants are encouraged to login to either website 15 minutes prior to the start of the webcast to register, download and install any necessary software.